Insiders · XBIO

Curtis Lockshin

Officer at Xenetic Biosciences, Inc. (XBIO)

Curtis Lockshin has filed 9 insider reports with the SEC since March 2021, as director at Phio Pharmaceuticals Corp. (PHIO) and officer at Xenetic Biosciences, Inc. (XBIO). The latest filing, on February 6, 2026, reports grant or award at Phio Pharmaceuticals Corp. (PHIO).

Filings
9
Companies
2
Bought on market
None
Sold on market
None

Companies where Curtis Lockshin is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Phio Pharmaceuticals Corp. logo
PHIO
Phio Pharmaceuticals Corp.
Director35,155$0.7203Feb 6, 2026
Xenetic Biosciences, Inc. logo
XBIO
Xenetic Biosciences, Inc.
Officer$1.53Dec 13, 2023

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Curtis Lockshin with

Other insiders at the same companies

Questions about Curtis Lockshin

What is Curtis Lockshin's role at Xenetic Biosciences, Inc.?
Curtis Lockshin reports to the SEC as officer at Xenetic Biosciences, Inc. (XBIO), according to the latest filing on December 13, 2023. Curtis Lockshin has also filed as director at Phio Pharmaceuticals Corp. (PHIO).
How many shares does Curtis Lockshin own?
After the latest filing that states it, Curtis Lockshin directly owned 35,155 shares of Phio Pharmaceuticals Corp. (PHIO). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Curtis Lockshin bought or sold stock recently?
No open-market purchases or sales by Curtis Lockshin are on file. The filings report grant or award.
How do I get alerts when Curtis Lockshin files?
Follow Curtis Lockshin on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Curtis Lockshin (SEC CIK 0001383556). Totals count each trade once, skipping amendments whose original is on file, from Mar 4, 2021 on. View on SEC EDGAR